Clovis Oncology (CLVS) Getting Somewhat Negative News Coverage, Report Finds

Media stories about Clovis Oncology (NASDAQ:CLVS) have been trending somewhat negative this week, AlphaOne Sentiment reports. AlphaOne, a unit of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Clovis Oncology earned a daily sentiment score of -0.03 on AlphaOne’s scale. AlphaOne also gave news coverage about the biopharmaceutical company an impact score of 70 out of 100, indicating that recent news coverage is likely to have an effect on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Alpha One Sentiment Analysis’s rankings:

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology (CLVS) traded up 0.45% during trading on Friday, hitting $59.97. 1,968,734 shares of the stock traded hands. The company’s 50 day moving average price is $54.46 and its 200 day moving average price is $55.14. The company’s market cap is $2.68 billion. Clovis Oncology has a 12 month low of $11.57 and a 12 month high of $74.94.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.43) by $0.10. The company had revenue of $7.05 million during the quarter, compared to analysts’ expectations of $6.04 million. On average, equities research analysts anticipate that Clovis Oncology will post ($4.95) EPS for the current fiscal year.

A number of research firms recently weighed in on CLVS. Leerink Swann began coverage on shares of Clovis Oncology in a research note on Tuesday. They issued an “outperform” rating and a $85.00 price objective for the company. J P Morgan Chase & Co set a $72.00 price objective on shares of Clovis Oncology and gave the stock a “buy” rating in a research note on Thursday, June 1st. Credit Suisse Group reaffirmed an “outperform” rating and issued a $88.00 price objective (up from $74.00) on shares of Clovis Oncology in a research note on Friday. Morgan Stanley upped their price objective on shares of Clovis Oncology from $68.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday, February 23rd. Finally, ValuEngine raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $63.33.

COPYRIGHT VIOLATION WARNING: This story was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $61.82, for a total value of $185,460.00. Following the completion of the transaction, the insider now directly owns 200,583 shares in the company, valued at $12,400,041.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 9,000 shares of company stock valued at $495,690 over the last quarter. Insiders own 17.40% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply